← Leaderboards
Madepalli Krishnappa Lakshmana
University Of California, San Diego
$3,132,279
Attributed
$3,557,140
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $776K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,557,140 · 8
By mechanism
R01$1,490,511 · 2
R21$1,455,928 · 4
R61$479,375 · 1
R03$131,326 · 1
Top collaborators
- Alexandros Makriyannis1 shared
- Adel Nefzi1 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Arpi Minassian$3,527,634
- Jared William Young$14,211,149
- Binhai Zheng$11,438,127
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProteinsCellsIn VivoMouse ModelBrainNeuronsInsightS DiseaseLigandsAffectReportingAnimal ModelBaseDesignGenesTransgenic MiceAmyloid Beta-Protein PrecursorPathogenesisAmyloidChronicNovel TherapeuticsPathologyHippocampus (Brain)
Grant awards (16)
Effect of small molecule activator of autophagy on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease$479,375
R61 · FY2025 · AG · contact PI
The potential benefits of autophagy activator TFEB in opioid use disorder in mice$405,625
R21 · FY2024 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,347
R01 · FY2024 · DA · contact PI
A LncRNA in Pulmonary Mucosal Immunity and HIV-Associated Comorbidities$179,600
R21 · FY2021 · AI · contact PI
A LncRNA in Pulmonary Mucosal Immunity and HIV-Associated Comorbidities$74,372
R21 · FY2021 · AI · contact PI
Novel role of TFEB in ADAM10 potentiation and proliferation of neural precursor cells relevant to Alzheimer's disease$221,250
R21 · FY2020 · AG · contact PI
Novel long noncoding RNAs in the airway mucous response$195,353
R21 · FY2020 · AI · contact PI
Novel long noncoding RNAs in the airway mucous response$195,353
R21 · FY2020 · AI · contact PI
Novel role of TFEB in ADAM10 potentiation and proliferation of neural precursor cells relevant to Alzheimer's disease$184,375
R21 · FY2019 · AG · contact PI
Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse model$271,120
R01 · FY2013 · AG · contact PI
Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse model$286,899
R01 · FY2012 · AG · contact PI
Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse model$286,899
R01 · FY2011 · AG · contact PI
Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse model$275,246
R01 · FY2010 · AG · contact PI
Effect of RanbpM on amyloid pathology in a mouse model of Alzheimer's disease$33,507
R03 · FY2009 · AG · contact PI
Effect of RanbpM on amyloid pathology in a mouse model of Alzheimer's disease$32,156
R03 · FY2009 · AG · contact PI
Effect of RanbpM on amyloid pathology in a mouse model of Alzheimer's disease$65,663
R03 · FY2008 · AG · contact PI